HK1203391A1 - Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51 - Google Patents

Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51

Info

Publication number
HK1203391A1
HK1203391A1 HK15104052.0A HK15104052A HK1203391A1 HK 1203391 A1 HK1203391 A1 HK 1203391A1 HK 15104052 A HK15104052 A HK 15104052A HK 1203391 A1 HK1203391 A1 HK 1203391A1
Authority
HK
Hong Kong
Prior art keywords
antiogenesis
beta1
antagonist
alpha
administration
Prior art date
Application number
HK15104052.0A
Other languages
English (en)
Chinese (zh)
Inventor
Feng Xiaodong
Original Assignee
California Northstate College Of Pharmacy Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/070339 external-priority patent/WO2013130168A1/en
Application filed by California Northstate College Of Pharmacy Llc filed Critical California Northstate College Of Pharmacy Llc
Publication of HK1203391A1 publication Critical patent/HK1203391A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK15104052.0A 2011-12-22 2015-04-27 Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51 HK1203391A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/374,369 US8946159B2 (en) 2011-12-22 2011-12-22 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
PCT/US2012/070339 WO2013130168A1 (en) 2012-02-28 2012-12-18 Medical protective cover

Publications (1)

Publication Number Publication Date
HK1203391A1 true HK1203391A1 (en) 2015-10-30

Family

ID=48655153

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104052.0A HK1203391A1 (en) 2011-12-22 2015-04-27 Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51

Country Status (6)

Country Link
US (5) US8946159B2 (xx)
EP (2) EP3777877B1 (xx)
JP (1) JP6224615B2 (xx)
CN (1) CN104159596B (xx)
HK (1) HK1203391A1 (xx)
WO (1) WO2013096335A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
MX2017002323A (es) * 2014-08-22 2017-08-02 Univ Nat Cheng Kung Variantes de desintegrina y usos farmaceuticos de las mismas.
US11597727B2 (en) 2018-03-13 2023-03-07 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
US11643388B2 (en) 2020-05-01 2023-05-09 The Regents Of The University Of California Inhibitors of alpha 2 beta 1 integrin and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019088A1 (en) 1992-03-17 1993-09-30 Board Of Regents, The University Of Texas System Neurotrophic peptides
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
ES2322723T5 (es) * 1998-05-08 2013-03-11 The Regents Of The University Of California Métodos para detectar e inhibir la angiogénesis
CA2400040A1 (en) * 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
US20040121031A1 (en) 2002-12-09 2004-06-24 Muhammed Majeed Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin
US7101707B2 (en) 2002-12-23 2006-09-05 Cedars-Sinai Medical Center Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances
UA88294C2 (ru) * 2004-03-24 2009-10-12 Фейсит Биотек Корпорейшен ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
ES2376556T3 (es) 2004-03-24 2012-03-14 Abbott Biotherapeutics Corp. Utilización de la anticuerpos anti-alfa5beta1 para inhibir la proliferación de las células cancerosas.
JP2008542445A (ja) * 2005-06-07 2008-11-27 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア α２β１／ＧＰＩａ−ＩＩａインテグリン阻害剤
WO2007083949A1 (en) 2006-01-19 2007-07-26 Eyegene Inc. Pharmaceutical composition for treating vascular-related diseases comprising peptide
MX2008012225A (es) 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
US20080267978A1 (en) 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
EP2268317B1 (en) 2008-03-14 2020-02-26 VisEn Medical, Inc. Integrin targeting agents and in vivo and in vitro imaging methods using the same
US20100105644A1 (en) 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
AU2009329035A1 (en) 2008-12-01 2011-06-23 Laila Pharmaceuticals Pvt. Ltd. Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
US8987493B2 (en) 2010-05-20 2015-03-24 Temple University—Of the Commonwealth System of Higher Education Process for synthesis of silane dipeptide analogs
US20110311335A1 (en) * 2010-06-21 2011-12-22 Douglas Wike Removable fastener
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
IL210587A0 (en) 2011-01-12 2011-03-31 Adel Jamil Hidmi Natural preparation for treatment of skin sores and lesions
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment

Also Published As

Publication number Publication date
WO2013096335A1 (en) 2013-06-27
WO2013096335A8 (en) 2014-03-27
JP2015506352A (ja) 2015-03-02
EP3777877A1 (en) 2021-02-17
EP2793924B1 (en) 2020-11-04
US8815805B2 (en) 2014-08-26
US11318184B2 (en) 2022-05-03
US8946159B2 (en) 2015-02-03
EP2793924A1 (en) 2014-10-29
US20130225495A1 (en) 2013-08-29
US10722555B2 (en) 2020-07-28
EP2793924A4 (en) 2015-08-26
US20150105320A1 (en) 2015-04-16
US20130165380A1 (en) 2013-06-27
US20220226431A1 (en) 2022-07-21
US12053504B2 (en) 2024-08-06
CN104159596B (zh) 2017-03-08
EP3777877B1 (en) 2024-08-07
US20200397856A1 (en) 2020-12-24
JP6224615B2 (ja) 2017-11-01
CN104159596A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
HK1232158A1 (zh) 用於治療肝癌的藥物
HK1217903A1 (zh) 施用吡非尼酮療法的方法
HK1205461A1 (en) Compositions and methods for ocular delivery of a therapeutic agent
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
EP2740796A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
EP2740794A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
HK1206937A1 (en) Methods of administering pirfenidone therapy
IL221556A (en) Kinase inhibitors and their use in cancer drug preparation
HK1200739A1 (en) Diagnostic methods and compositions for treatment of cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2709614A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
IL232434A0 (en) Medicine for medical treatment and/or improvement of sepsis
HK1203391A1 (en) Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51
EP2753337A4 (en) COMPOSITIONS COMPRISING BETA-GLUCANS AND METHODS OF USE
HK1212225A1 (en) Therapeutic formulation and methods of treatment
HK1201730A1 (en) Treatment agent and or prophylactic agent for side effects of cancer drugs
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2793955A4 (en) RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER